Skip to NavigationSkip to content

Vectura asthma treatment fails at Phase III

Published on 30/08/16 at 09:33am

Respiratory drug specialist Vectura’s asthma treatment Flutiform was unsuccessful in meeting the primary endpoint in its Phase III trial conducted by European partner Mundipharma.

The inhaler failed to show a “statistically significant” superiority in reducing the yearly degradation of moderate to severe chronic obstructive pulmonary disease (COPD) compared to mono-component LABA treatment.

1,767 randomly selected patients from 16 countries took part in Phase III of the trial, a double-blind study comparing Flutiform to Formoterol Fumarate Dihydrate, a treatment for COPD including chronic bronchitis.

The company has reported that Mundipharma are still in the process of analysing the trial’s other endpoints, but the failure of its primary objective means it will not be filing a regulatory request for the treatment in Europe.

"Whilst this result is disappointing, Flutiform continues to grow strongly based on the approved asthma indication, which continues to underpin our expectations for future growth of the product," commented CEO James Ward-Lilley.

The company was nevertheless the biggest loser at the London Stock Exchange on Tuesday, with shares down 10% to 124.8p.

Matt Fellows

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches